MK-8527
Based on 1 Customer Validation
MK-8527 is an orally active HIV inhibitor and nucleoside reverse transcriptase translocation inhibitor (NRTTI) with antiviral activity. MK-8527 has a similar inhibitory mechanism to ISL (HY-104012).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.99%
- CAS. Nr.: 1810869-23-8
- Formel: C13H13ClN4O3
- Molecular Weight:308.72
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
In Vitro
MK-8527 causes loss of lymphocytes[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 1810869-23-8
-
Appearance Solid
-
Molecular Weight 308.72
-
Formel C13H13ClN4O3
-
Color White to off-white
-
SMILES
OC[C@]1(C#C)[C@@H](O)C[C@H](N2C3=NC(Cl)=NC(N)=C3C=C2)O1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (323.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Gillespie SW, et al. Islatravir: evaluation of clinical development for HIV and HBV. Expert Opin Investig Drugs. 2024 Feb;33(2):85-93. [Content Brief]
[2]. Liu AY, et al. CROI 2024: Global Epidemiology and Prevention of HIV and Other Sexually Transmitted Diseases. Top Antivir Med. 2024 Jul 17;32(3):447-482. [Content Brief]
[3]. Gunaratne SH, et al. CROI 2024: The Challenges of Sustained Viral Suppression, Advanced HIV Disease, and Ending the HIV Epidemic Targets. Top Antivir Med. 2024 Aug 12;32(4):542-567. [Content Brief]
[4]. Zhernov YV, et al. Microbicides for Topical HIV Immunoprophylaxis: Current Status and Future Prospects. Pharmaceuticals (Basel). 2024 May 22;17(6):668. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2392 mL | 16.1959 mL | 32.3918 mL | 80.9795 mL |
| 5 mM | 0.6478 mL | 3.2392 mL | 6.4784 mL | 16.1959 mL | |
| 10 mM | 0.3239 mL | 1.6196 mL | 3.2392 mL | 8.0980 mL | |
| 15 mM | 0.2159 mL | 1.0797 mL | 2.1595 mL | 5.3986 mL | |
| 20 mM | 0.1620 mL | 0.8098 mL | 1.6196 mL | 4.0490 mL | |
| 25 mM | 0.1296 mL | 0.6478 mL | 1.2957 mL | 3.2392 mL | |
| 30 mM | 0.1080 mL | 0.5399 mL | 1.0797 mL | 2.6993 mL | |
| 40 mM | 0.0810 mL | 0.4049 mL | 0.8098 mL | 2.0245 mL | |
| 50 mM | 0.0648 mL | 0.3239 mL | 0.6478 mL | 1.6196 mL | |
| 60 mM | 0.0540 mL | 0.2699 mL | 0.5399 mL | 1.3497 mL | |
| 80 mM | 0.0405 mL | 0.2024 mL | 0.4049 mL | 1.0122 mL | |
| 100 mM | 0.0324 mL | 0.1620 mL | 0.3239 mL | 0.8098 mL |
MK-8527 Related Classifications
HY-158128 Related Classifications
Powered by Bioz